ValuEngine cut shares of Avenue Therapeutics (NASDAQ:ATXI) from a buy rating to a hold rating in a research report released on Wednesday morning.
A number of other analysts have also recently weighed in on the company. Oppenheimer set a $10.00 price objective on Avenue Therapeutics and gave the stock a buy rating in a research report on Thursday, November 15th. HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Avenue Therapeutics in a research report on Wednesday, August 15th.
Avenue Therapeutics stock opened at $5.28 on Wednesday. Avenue Therapeutics has a 1-year low of $2.08 and a 1-year high of $6.00.
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
See Also: Liquidity
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.